Also known as: Danaher
Danaher is an American healthcare and life-sciences company developing products across biotechnology, diagnostics, and related scientific markets. Headquartered in Washington, D.C., it operates globally through multiple divisions and subsidiaries. The company is publicly traded on the NYSE under DHR.
Global virus filters markets are projected for strong growth through 2035, with CAGRs of 7.2% to 8.2%, driven by expanding biologics production and stringent regulatory mandates for viral safety. Monoclonal antibody manufacturing remains the largest segment, while advanced therapy medicinal products are the fastest-growing area of demand.
Danaher agreed to acquire Masimo for $9.9 billion, paying $180 per share to expand its diagnostics portfolio into blood oxygen monitoring and patient monitoring devices. Danaher also launched nearly €3 billion in senior notes to help fund the deal, which is expected to close by the second half of 2026.
The mRNA synthesis and manufacturing market is projected to grow from USD 2.23 billion in 2024 to USD 2.96 billion by 2029 at a 5.8% CAGR. Consumables led in 2023, while Asia Pacific is expected to be the fastest-growing region.
Danaher guided for 3% to 6% revenue growth and adjusted EPS of $8.35 to $8.50 in 2026 as biopharma spending shows signs of recovery. Recent results included $6.8 billion in quarterly sales, 2.5% core revenue growth and $1.8 billion in free cash flow.
Danaher approved a $0.40 quarterly dividend and completed a $9.9 billion Masimo acquisition to expand into patient monitoring, while its Life Sciences segment operating profit fell 57% in 2025 to $520 million.
The UK and US announced a pharmaceuticals agreement featuring zero tariffs and a 25% increase in UK spending on innovative medicines. Major pharma M&A deals and regulatory reforms are reshaping the industry in early 2026.
